News

Article

Pharmaceutical Technology

Pharmaceutical Technology-11-02-2004
Volume28
Issue 11

Method Validation by Phase of Development: An Acceptable Analytical Practice

This article provides guidance for minimally acceptable method validation practices and a foundation for assessing the risks and benefits associated with method validation programs.

External Link - article-132387.pdf

Articles in this issue
Still Waiting for Answers
Method Validation by Phase of Development: An Acceptable Analytical Practice
Comparing and Contrasting Barrier Isolator Decontamination Systems
November 2004
In the Spotlight-November 2004
Searching for a Viable Business Model
Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development
FDA Moves To Implement New GMP Policies

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Simona Guidi, Associate Director, ProPharma
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 5th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 5th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
White House | Image Credit: © Zack Frank - stock.adobe.com
August 5th 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery
If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 5th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Kratom or Mitragyna speciosa on natural background. | Image Credit: © wasanajai - stock.adobe.com
August 5th 2025

FDA Seeks Scheduling Action to Control Harmful Kratom Plant Byproduct

Patrick Lavery
7-OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services. | Image Credit: © Tada Images - stock.adobe.com
August 5th 2025

3 Reasons FDA Says Quality Investments Are Essential for Drug Manufacturers and Patients

Patrick Lavery
FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and help prevent drug shortages.